Immunocore Holdings plc Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 9 | -$0.29 | -$0.29 | -$0.29 |
Q2 2024 | 8 | -$0.38 | -$0.38 | -$0.38 |
Q3 2024 | 10 | -$0.39 | -$0.12 | -$0.25 |
Q4 2024 | 8 | -$0.33 | -$0.33 | -$0.33 |
Q1 2025 | 9 | -$0.33 | -$0.33 | -$0.33 |
Q2 2025 | 9 | -$0.32 | -$0.32 | -$0.32 |
Q3 2025 | 9 | -$0.37 | -$0.37 | -$0.37 |
Q4 2025 | 9 | -$0.45 | -$0.45 | -$0.45 |
Q1 2026 | 8 | -$0.50 | -$0.50 | -$0.50 |
Q2 2026 | 8 | -$0.53 | -$0.53 | -$0.53 |
Q3 2026 | 8 | -$0.57 | -$0.57 | -$0.57 |
Q4 2026 | 8 | -$0.59 | -$0.59 | -$0.59 |
Immunocore Holdings plc Earnings Date And Information
Immunocore Holdings plc last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.23 earnings per share for the quarter, topping analysts' consensus estimates of $-0.45 by $0.22. The company had revenue of 75.40 M for the quarter and had revenue of 249.43 M for the year. Immunocore Holdings plc has generated $-1 earnings per share over the last year ($-1.13 diluted earnings per share) and currently has a price-to-earnings ratio of -25.69. Immunocore Holdings plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Immunocore Holdings plc Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/08/2024 | Q2 2024 | -$0.45 | -$0.23 | 0.22 | $74.58 M | $75.40 M |
05/08/2024 | Q1 2024 | -$0.33 | -$0.49 | -0.16 | $70.50 M | |
02/28/2024 | Q4 2023 | -$0.28 | -$0.54 | -0.26 | $105.64 M | |
11/07/2023 | Q3 2023 | -$0.32 | $0.05 | 0.37 | $62.79 M | $62.62 M |
05/10/2023 | Q2 2023 | -$0.30 | -$0.37 | -0.07 | $57.76 M | $60.48 M |
03/01/2023 | Q1 2023 | -$0.00 | -$0.43 | -0.43 | $55.06 M | |
11/09/2022 | Q4 2022 | -$0.26 | -$0.54 | -0.28 | $48.06 M | |
08/10/2022 | Q3 2022 | -$0.72 | $0.13 | 0.85 | $37.39 M | $41.20 M |
05/11/2022 | Q2 2022 | -$1.07 | -$0.14 | 0.93 | $20.97 M | $32.00 M |
03/03/2022 | Q1 2022 | -$1.08 | -$0.37 | 0.71 | $22.47 M | |
11/10/2021 | Q4 2021 | -$0.85 | -$0.90 | -0.05 | $6.59 M | |
08/11/2021 | Q3 2021 | -$0.95 | -$0.69 | 0.26 | $7.36 M | $5.92 M |
05/12/2021 | Q2 2021 | -$0.83 | -$0.75 | 0.08 | $7.83 M | $5.73 M |
05/12/2021 | Q1 2021 | -$0.83 | -$0.76 | 0.07 | $8.27 M | |
03/25/2021 | Q4 2020 | -$1.05 | -$0.49 | 0.56 | $7.42 M | |
09/29/2020 | Q3 2020 | -$0.61 | $6.65 M | |||
06/29/2020 | Q2 2020 | -$0.63 | $7.79 M | |||
03/30/2020 | Q1 2020 | -$0.68 | $8.26 M | |||
12/30/2019 | Q4 2019 | -$0.95 | $5.64 M |
Immunocore Holdings plc Earnings: Frequently Asked Questions
-
When is Immunocore Holdings plc's earnings date?
Immunocore Holdings plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
Did Immunocore Holdings plc beat their earnings estimates last quarter?
In the previous quarter, Immunocore Holdings plc (:IMCR) reported $-0.23 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.45 by $0.22.
-
How can I listen to Immunocore Holdings plc's earnings conference call?
The conference call for Immunocore Holdings plc's latest earnings report can be listened to online.
-
How can I read Immunocore Holdings plc's conference call transcript?
The conference call transcript for Immunocore Holdings plc's latest earnings report can be read online.
-
How much revenue does Immunocore Holdings plc generate each year?
Immunocore Holdings plc (:IMCR) has a recorded annual revenue of $249.43 M.
-
How much profit does Immunocore Holdings plc generate each year?
Immunocore Holdings plc (:IMCR) has a recorded net income of $249.43 M. Immunocore Holdings plc has generated $-1.13 earnings per share over the last four quarters.
-
What is Immunocore Holdings plc's price-to-earnings ratio?
Immunocore Holdings plc (:IMCR) has a price-to-earnings ratio of -25.69 and price/earnings-to-growth ratio is -5.48.